News from sangamo biosciences, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 05, 2017, 08:00 ET Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational...

Jan 04, 2017, 04:05 ET Sangamo BioSciences Announces Presentation At The 35th Annual J.P. Morgan Healthcare Conference

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D, Sangamo's...

Dec 01, 2016, 07:00 ET Sangamo BioSciences Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today key leadership appointments to strengthen the...

Nov 30, 2016, 07:00 ET Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ

Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that its collaborative zinc finger nuclease...

Nov 10, 2016, 04:03 ET Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's...

Oct 26, 2016, 04:03 ET Sangamo BioSciences Reports Third Quarter 2016 Financial Results

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its third quarter 2016 financial results and...

Oct 19, 2016, 04:03 ET Sangamo BioSciences Announces Third Quarter 2016 Conference Call and Webcast

Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that the company will release its third quarter...

Oct 17, 2016, 04:03 ET Sangamo BioSciences Announces Participation In Upcoming Scientific Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that members of the Company's research and...

Sep 29, 2016, 04:03 ET Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's...

Sep 06, 2016, 07:00 ET Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA)...

Aug 31, 2016, 04:03 ET Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's...

Aug 09, 2016, 04:03 ET Sangamo BioSciences Announces Presentation At The 2016 Wedbush PacGrow Healthcare Conference

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's...

Aug 03, 2016, 04:03 ET Sangamo BioSciences Reports Second Quarter 2016 Financial Results

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its second quarter 2016 financial results and...

Jul 27, 2016, 04:03 ET Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the company will release its second quarter...

Jul 26, 2016, 11:45 ET Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of Hemophilia A

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the presentation of preclinical data that...

Jul 12, 2016, 04:03 ET Sangamo BioSciences Announces Participation At Upcoming Scientific Conferences in July

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that members of the Company's research and...

Jun 20, 2016, 07:00 ET Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has...

Jun 01, 2016, 07:00 ET Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander 'Sandy'...

Jun 01, 2016, 04:03 ET Sangamo BioSciences Announces Presentation at the Jefferies 2016 Healthcare Conference

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's founder and...

May 10, 2016, 04:03 ET Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and...

May 09, 2016, 07:00 ET Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic® Programs In Multiple Presentations At Annual Meeting of the American Society of Gene and Cell Therapy

Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, presented new preclinical data from the Company's proprietary In...

May 02, 2016, 04:05 ET Sangamo BioSciences Reports First Quarter 2016 Financial Results

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its first quarter 2016 financial results and...

Apr 28, 2016, 04:03 ET Sangamo BioSciences Announces Presentation At The Deutsche Bank 41st Annual Health Care Conference

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and...

Apr 25, 2016, 04:03 ET Sangamo BioSciences Announces First Quarter 2016 Conference Call and Webcast

Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its first quarter...

Apr 18, 2016, 04:03 ET Sangamo BioSciences Announces Presentations On ZFP Therapeutic® Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from several ZFP Therapeutic programs will be ...